| C M | 10/616 60E | • | Dane ' |
|-------|------------|---|--------|
| O.IN. | 10/010,005 | 1 | ayc |

LISTING OF CLAIMS

- 1. (Canceled)
- 2. (Canceled)
- 3. (Currently Amended) An essentially pure compound having the following structure of Formula II:

wherein R¹ is t-butyl group [-CH₂-CH(CH₃)₂] isobutyl (-CH₂-CH(CH₃)₂).

- 4. (Currently Amended) A pharmaceutical composition comprising [[an]] <u>a</u> therapeutically effective amount of the <u>essentially pure</u> compound as claimed in claim 1 claim 3 together with at least one pharmaceutically acceptable excipient.
- 5. (Currently Amended) The pharmaceutical composition of claim 4, wherein the composition is in oral form.
- 6. (Currently Amended) The pharmaceutical composition of claim 4, wherein the composition is in intravenous form.

7. (Currently Amended) The pharmaceutical composition of claim4. wherein the composition is in subcutaneous form.

- 8. (Currently Amended) The pharmaceutical composition of claim 4, wherein the composition is in intramuscular form.
- 9. (Currently Amended) The pharmaceutical composition of claim 4, wherein the composition is in inhalation form.
- 10. (Canceled)
- 11. (Currently Amended) The chemically modified compound according to claim 10 pharmaceutical composition of claim 4, wherein said composition is chemically modified as a therapeutically effective compound is a salt.
- 12. (Canceled)
- 13. (Currently Amended) A method of obtaining a compound as claimed in claim 1 an essentially pure compound of Formula II:

wherein R^1 is isobutyl (- CH_2 - $CH(CH_3)_2$), comprising extracting and purifying the compound from Piper laetispicum of Piperaceae family.

14. (Currently Amended) A method of treating a disease characterized as mental disorder, comprising administering to a patient <u>suffering from said disease</u> with a therapeutically effective amount of an essentially pure compound of <u>Formula I:</u>

$$0 \xrightarrow{3'} \xrightarrow{2'} \xrightarrow{11} \xrightarrow{9} \xrightarrow{7} \xrightarrow{5} \xrightarrow{3} \xrightarrow{2} Y - R^{1}$$

$$0 \xrightarrow{4'} \xrightarrow{5'} \xrightarrow{6'} \xrightarrow{10} \xrightarrow{8} \xrightarrow{10} \xrightarrow{8} \xrightarrow{10} 10} \xrightarrow{10} \xrightarrow{10} \xrightarrow{10} \xrightarrow{10} \xrightarrow{10} \xrightarrow{10} \xrightarrow{10} \xrightarrow{10} \xrightarrow{10} 10} \xrightarrow{10} \xrightarrow{10} \xrightarrow{10} \xrightarrow{10} 10} \xrightarrow$$

wherein R¹ is selected from the group consisting of hydrogen, C₁₋₁₀ alkyl and aromatic cyclic group, R² is selected from the group consisting of hydrogen, OR³, NHR³, and halogen,

Z is selected from the group consisting of =O, OH, NHR³, SH, and SR³, wherein R³ is C₁₋₁₀ alkyl or aromatic cyclic group, (C₇-C₈)_n includes at least one single bond or at least one double bond, n is an integer having a value of 0 to 10, and Y is selected from the group consisting of NH, NR³-, O, and S. with said disease an effective amount of a compound as claimed in claim 1.

- 15. (Original) The method of claim 14, wherein the disease is depression.
- 16. (Original) The method of claim 14, wherein the disease is psychopathic disease.
- 17. (Original) The method of claim 14, wherein the disease is Alzheimer's disease.

18. (Currently Amended) A method of alleviating a symptom characterized as inflammation and pain, comprising administering to a subject <u>suffering from said symptom with a therapeutically effective amount of an essentially pure compound of Formula I:</u>

$$0 \xrightarrow{3'} \xrightarrow{2'} \xrightarrow{1} \xrightarrow{11} \xrightarrow{9} \xrightarrow{7} \xrightarrow{5} \xrightarrow{3} \xrightarrow{2} Y - R^{1}$$

$$0 \xrightarrow{4'} \xrightarrow{5'} \xrightarrow{6'} \xrightarrow{10} \xrightarrow{8} \xrightarrow{10} \xrightarrow{8} \xrightarrow{10} 10} \xrightarrow{10} \xrightarrow{10} \xrightarrow{10} \xrightarrow{10} \xrightarrow{10} \xrightarrow{10} \xrightarrow{10} 10} \xrightarrow{10} \xrightarrow{10} \xrightarrow{10} \xrightarrow{10}$$

wherein R¹ is selected from the group consisting of hydrogen, C₁₋₁₀ alkyl and aromatic cyclic group, R² is selected from the group consisting of hydrogen, OR³, NHR³, and halogen,

Z is selected from the group consisting of =O, OH, NHR³, SH, and SR³, wherein R³ is C₁₋₁₀ alkyl or aromatic cyclic group, (C₇-C₈)_n includes at least one single bond or at least one double bond, n is an integer having a value of 0 to 10, and Y is selected from the group consisting of NH, NR³-, O, and S. with said symptom an effective amount of a compound as claimed in claim 1.